Opinion in Spain

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Allfunds Bank: UK offering may struggle to replicate Spanish success

Allfunds Bank, a joint venture between Sanpaolo IMI and Abbey's parent Grupo Santander, will launch its third-party distribution platform in the UK. The venture accounts for about half of the third-party fund distribution market in Spain, but the company is unlikely to enjoy the same strong performance in the UK.

Published By Datamonitor
22 Jun 2005
Expert View
Expert View

Alliance & Leicester takeover could signal an end to UK banking competition

Banco Santander announced on July 14 that it had, rather hastily, agreed a deal to take over Alliance & Leicester for a reported GBP1.2 billion. While regulators welcome the move, the deal also symbolizes another nail in the coffin for innovative competition in the UK banking market.

Published By Datamonitor
21 Jul 2008
CommentWire
CommentWire

Altadis: getting hooked on non-tobacco logistics

Tobacco giant Altadis has shown continuing revenue increases in its non-tobacco related logistics services. The growth is largely due to its acquistion of Grupo Burgai in 2001. With the division as a whole performing well, Altadis must concentrate on efficiency and ensure that lower margin activities do not hamper its capability for reinvestment.

Published By Datamonitor
02 Sep 2002
ResearchWire
ResearchWire

Anticonvulsants: potential sales growth in off-label expansion

Published By Datamonitor
31 Jul 2001
ResearchWire
ResearchWire

Antidepressants: noradrenergics sales to rise

Published By Datamonitor
15 Mar 2001
ResearchWire
ResearchWire

Antimetabolites: market will be worth $1.9 billion in 2007

Published By Datamonitor
12 Jun 2001
ResearchWire
ResearchWire

Antipsychotics: growth in sales but only until 2006

Published By Datamonitor
20 Apr 2001
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.